Superficial soft tissue sarcomas : 10-year survival outcomes

Tools

Tolia, Maria and Gkantaifi, Areti and Hayward, Larry and Gupta, Girish and Kyriazoglou, Anastasios and Mauri, Davide and Nixon, Ioanna (2023) Superficial soft tissue sarcomas : 10-year survival outcomes. Oncology Letters, 25 (3). 96. ISSN 1792-1082 (https://doi.org/10.3892/ol.2023.13682)

[thumbnail of Tolia-etal-OL-2023-Superficial-soft-tissue-sarcomas]
Preview
 Text. Filename: Tolia_etal_OL_2023_Superficial_soft_tissue_sarcomas.pdf
Final Published Version
License: Strathprints license 1.0
Download (334kB)| Preview

Abstract

Cutaneous sarcomas comprise a broad group of rare, heterogeneous mesenchymal tumours. The present report describes a single centre experience regarding the management and the outcomes of patients with superficial soft tissue sarcomas (SSTS). Key prognostic factors in predicting overall survival (OS) and local relapse-free survival were determined. Data from 66 patients with SSTS treated surgically within Edinburgh and Lothian were collected in the context of a service evaluation. Patient demographics, tumour specifics and treatment, as well as 5-year OS and local recurrence, were analysed. Kaplan-Meier analysis was applied for survival curves, and mortality rate estimation and Cox regression were used to establish independent predictors. The mean estimated OS time was 57.2 months, with a 95% CI between 55.0 and 59.5 months. The median OS time could not be estimated because there is no time point during which the survival function has a value <50%. The death risk for a person with SSTS was increased by 7.3% (odds ratio, 1.073; 95% CI, 1.012-1.138) for every additional year of life. The estimated mean local relapse time was 58.5 months, with a 95% CI between 56 and 61 months. The median local relapse time could not be estimated since there is no time point during which the local recurrence function has a value <50%. In conclusion, out of all independent variables considered, none could statistically significantly explicate local relapse recurrence time. It is important that these rare tumours are treated in the context of a multidisciplinary team with consensus guidelines to assist decision-making.

ORCID iDs

Tolia, Maria, Gkantaifi, Areti, Hayward, Larry, Gupta, Girish, Kyriazoglou, Anastasios, Mauri, Davide and Nixon, Ioanna ORCID logoORCID: https://orcid.org/0000-0003-3223-0700;
CORE (COnnecting REpositories)